Compare TG Therapeutics Inc (TGTX) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Valero Energy Corporation — how do they compare? TG Therapeutics Inc trades at $55.14 (market cap $8.16B), while Valero Energy Corporation trades at $434.88 (market cap $127.78B). The key difference: Valero Energy Corporation is far larger — about 15.7× TG Therapeutics Inc's market cap, and Valero Energy Corporation pays a 1.08% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Valero Energy Corporation for 56 Days on average.
| TGTX | VLO | |
|---|---|---|
Market Cap | $8.16B | $127.78B |
Volume | 1,735,121 | 2,570,225 |
Sector | Health | Energy |
52-Week High | $59.06 | $443.80 |
52-Week Low | $26.94 | $156.39 |
Typical Hold Time | 16 Days | 56 Days |
Enterprise Value | $8.37B | $131.26B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Valero Energy (VLO) trades at $433.75, up 2.28% today, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages, though RSI levels suggest overbought conditions. Fundamentally, VLO has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $20.17 EPS. Revenue declined to $122.69B in 2025, but net income margin improved to 5.17%. The company maintains a solid balance sheet with a debt-to-asset ratio of 18.31% as of 2024.
VLO's outlook is supported by robust refining margins and a favorable analyst consensus, with 54% buy ratings and a $408.10 price target. Key risks include potential diesel export bans and volatile energy markets. Investors should weigh strong cash flow projections against cyclical industry headwinds for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
